Summit Therapeutics Inc.
SMMT
Updated: 23/09/2026, 18:01:12
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
No summaries found.
- Share price
- $16.29
- Market cap
- $13.00B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Robert W. Duggan
- Employees
- 265
- IPO date
- 05/03/2015
- Beta
- -1.243
- Last dividend
- $0.00
- Day range
- $16.28 – $17.46
- 52-week range
- $12.07 – $29.23
- 1-day performance
- -4.85%
- 1-year performance
- 34.96%
- Current drawdown (1Y)
- -44.27%
- CIK
- 0001599298
- CUSIP
- 86627T108
- ISIN
- US86627T1088
- Created
- 07/12/2025, 14:17:49
- Last update
- 23/09/2026, 18:01:12
Track Summit Therapeutics Inc. with an AI analyst
See which prediction-market events move SMMT, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Director's $50M Investment in Summit Therapeutics (NASDAQ:SMMT) Signals Confidence
Market Data • Market Data • 12/06/2026, 19:00:30
Summit Therapeutics Inc. (SMMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 08/06/2026, 17:08:30
Summit Therapeutics Inc. (SMMT) Discusses Plenary Session Updates and Recent Clinical Data Following Major Oncology Congress Transcript
Seeking Alpha • STOCK • 01/06/2026, 15:54:03
This Emerging Risk Is Unlike Anything the Biotech Industry Has Ever Experienced
Fool - Investing News • STOCK • 31/05/2026, 15:45:00
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
Business Wire • STOCK • 31/05/2026, 11:06:00
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
CNBC • STOCK • 31/05/2026, 10:00:02
Here's Why You Should Add SMMT Stock to Your Portfolio Now
Zacks Investment Research • STOCK • 22/05/2026, 12:31:23
SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab Setback
Zacks Investment Research • STOCK • 04/05/2026, 16:15:18
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026
Business Wire • STOCK • 30/04/2026, 18:32:00
SMMT Stock Up 24% in Three Months: Here's What You Need to Know
Zacks Investment Research • STOCK • 16/04/2026, 14:30:46
Summit Therapeutics Inc. (NASDAQ:SMMT) Gains Momentum with Analyst Support and Promising Drug Pipeline
Market Data • Market Data • 08/04/2026, 22:22:03
Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst
Benzinga • STOCK • 08/04/2026, 16:27:17